Idhifa (enasidenib Mesylate) – Market Withdrawal And Continued Access

IDHIFA Recall Summary IDHIFA (enasidenib mesylate), a cancer medication, is being withdrawn from the Canadian market due to new safety information. This affects all IDHIFA products distributed across Canada. Patients currently using this medication should consult their healthcare provider about this withdrawal.

Product

IDHIFA (enasidenib)

Reason

New safety information - Product withdrawal

Category

drug recall

Country

Canada

Agency

HC-DRUGS

Recall date

2023-06-08

Status

Ongoing

Distribution

Canada-wide

Official recall notice from HC-DRUGS

Recall details on Nibble Recalls: https://trynibble.app/recalls/27d0bb1c-f26e-4b10-970d-ed26590874c6